Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 55.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 107,936 shares of the company's stock after buying an additional 38,527 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.39% of Castle Biosciences worth $2,876,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. lifted its stake in Castle Biosciences by 11.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company's stock valued at $158,000 after buying an additional 604 shares in the last quarter. Truist Financial Corp lifted its stake in Castle Biosciences by 4.6% in the 4th quarter. Truist Financial Corp now owns 21,303 shares of the company's stock valued at $568,000 after buying an additional 928 shares in the last quarter. Bailard Inc. lifted its stake in Castle Biosciences by 12.5% in the 4th quarter. Bailard Inc. now owns 9,900 shares of the company's stock valued at $264,000 after buying an additional 1,100 shares in the last quarter. Perkins Capital Management Inc. lifted its stake in Castle Biosciences by 4.7% in the 4th quarter. Perkins Capital Management Inc. now owns 34,165 shares of the company's stock valued at $910,000 after buying an additional 1,525 shares in the last quarter. Finally, R Squared Ltd purchased a new stake in Castle Biosciences in the 4th quarter valued at approximately $42,000. Hedge funds and other institutional investors own 92.60% of the company's stock.

Insider Transactions at Castle Biosciences

In other news, insider Derek J. Maetzold sold 22,639 shares of the company's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $20.12, for a total transaction of $455,496.68. Following the completion of the sale, the insider now directly owns 80,465 shares in the company, valued at $1,618,955.80. This represents a 21.96 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total value of $221,613.39. The disclosure for this sale can be found here. Insiders sold a total of 35,321 shares of company stock worth $774,644 in the last ninety days. Insiders own 7.20% of the company's stock.

Wall Street Analyst Weigh In

CSTL has been the topic of a number of recent research reports. Guggenheim set a $30.00 target price on Castle Biosciences and gave the company a "buy" rating in a research note on Friday, March 28th. Robert W. Baird boosted their price target on Castle Biosciences from $36.00 to $37.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Finally, Stephens reiterated an "overweight" rating and issued a $41.00 price target on shares of Castle Biosciences in a report on Thursday, January 2nd. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $38.75.

Castle Biosciences Trading Down 2.6 %

Shares of CSTL stock traded down $0.54 on Monday, reaching $20.09. 489,240 shares of the stock were exchanged, compared to its average volume of 390,278. The stock has a market cap of $579.50 million, a P/E ratio of 100.46 and a beta of 1.11. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. The firm has a 50 day moving average of $20.90 and a two-hundred day moving average of $26.48. Castle Biosciences, Inc. has a 1-year low of $16.97 and a 1-year high of $35.84.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.